Imagin Medical Inc. Stock

Equities

IME

CA45250L2049

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange 02:29:20 2024-02-02 pm EST 5-day change 1st Jan Change
0.015 CAD -.--% Intraday chart for Imagin Medical Inc. -.--% -70.00%
Sales 2021 - Sales 2022 - Capitalization 3.14M 4.29M
Net income 2021 -11M -15.03M Net income 2022 -2M -2.73M EV / Sales 2021 -
Net Debt 2021 11.46M 15.66M Net Debt 2022 13.08M 17.88M EV / Sales 2022 -
P/E ratio 2021
-0.37 x
P/E ratio 2022
-1.16 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 88.73%
More Fundamentals * Assessed data
Dynamic Chart
Imagin Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Imagin Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Imagin Medical Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
Imagin Medical Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Imagin Medical Inc. Auditor Raises 'Going Concern' Doubt CI
Imagin Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022 CI
Imagin Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022 CI
Imagin Medical Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021 CI
Imagin Medical Inc. Reports Earnings Results for the Full Year Ended September 30, 2021 CI
Imagin Medical Inc. Auditor Raises 'Going Concern' Doubt CI
Imagin Medical Inc. Announces Board Changes CI
Imagin Medical Inc. announced that it has received $2.9005 million in funding CI
Imagin Medical Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021 CI
Imagin Medical Inc. Reports the Final Design of the i/Blue Imaging System Is on Target to Be Demonstrated At the American Urology Association Annual Meeting in September CI
Imagin Medical Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021 CI
More news
3 months-40.00%
6 months-82.35%
Current year-70.00%
More quotes
Current year
0.01
Extreme 0.01
0.07
1 year
0.01
Extreme 0.01
0.19
3 years
0.01
Extreme 0.01
0.70
5 years
0.01
Extreme 0.01
1.90
10 years
0.01
Extreme 0.01
8.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 75 16-02-08
Director of Finance/CFO - 18-01-14
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 66 18-10-01
Chief Executive Officer 75 16-02-08
Director of Finance/CFO - 18-01-14
More insiders
Imagin Medical Inc. is a urologic oncology company. It is engaged in developing technologies to better visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer. Its first product, enCAGE Coil, is designed to eliminate the limitations of other methods of prostate cancer treatment that can cause erectile dysfunction and urinary incontinence. The device is a disposable, focal therapy, precision ablation system that will deliver bipolar, radio frequency energy through a distinctive coil electrode, or cage. It enables the surgeon to preset margins for precise tissue targeting. Its second product, the i/Blue Imaging System, will bring several key technological advancements that improve the utility of blue light imaging for visualizing bladder cancer. The i/Blue System delivers blue light imaging technology in a more versatile, practical, and accessible format and is designed to work with existing fiberoptic endoscopes on the market.
More about the company